Kendall Capital Management Makes New $1.26 Million Investment in Collegium Pharmaceutical, Inc. $COLL

Kendall Capital Management purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 34,730 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,257,000. Kendall Capital Management owned about 0.11% of Collegium Pharmaceutical as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth $196,972,000. Rubric Capital Management LP raised its holdings in shares of Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the period. Vanguard Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after purchasing an additional 377,073 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after purchasing an additional 18,160 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $27.11 on Friday. The firm has a market capitalization of $882.70 million, a PE ratio of 21.86 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a one year low of $25.47 and a one year high of $50.79. The stock’s 50 day moving average price is $33.67 and its 200 day moving average price is $35.78. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. Collegium Pharmaceutical’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $1.68 earnings per share. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.